We are delighted to announce that Neotherix has been short-listed in the final round of the 2018 OBN (Oxfordshire Bioscience Network) Awards for our involvement in the NIHR-funded collaborative project "Transforming treatment of fistula-in-ano (FIA): a novel bioresorbable seton scaffold device" (see our previous news item regarding this project). OBN is a membership organisation supporting and bringing together the UK's innovative life sciences companies, corporate partners and investors. Neotherix is one of four finalists in the Best Innovative Medtech Company category, which will be awarded on the basis of innovativeness and potential impact of the technology. The winners of this and other awards for 2018 will be announced at the awards evening taking place on Thursday 11 October at The Examinations Schools in Oxford. Dr John Harris, CEO of OBN (UK) said: "We received the highest number of qualifying entries for the OBN Awards this year, up a staggering 40% on last year's total. The standard of entries across all categories was extremely high and we are encouraged about the level of exciting new innovation and positive growth we are seeing in UK Life Sciences. We look forward to celebrating with all our finalists on 11 October at the Examination Schools in Oxford." For more information please visit the OBN Awards website  . |
